REYON Pharmaceutical Co., Ltd. (102460.KS)
KRW 13020.0
(-2.18%)
KRW 13020.0
(-2.18%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 200.94 Billion KRW | 3.5% |
| 2022 | 194.15 Billion KRW | 38.12% |
| 2021 | 140.57 Billion KRW | 197.58% |
| 2020 | 47.23 Billion KRW | 69.74% |
| 2019 | 27.83 Billion KRW | 5.06% |
| 2018 | 26.48 Billion KRW | -20.95% |
| 2017 | 33.51 Billion KRW | 7361.46% |
| 2016 | 449.1 Million KRW | 167.79% |
| 2015 | -662.49 Million KRW | -105.15% |
| 2014 | 12.85 Billion KRW | -37.67% |
| 2013 | 20.62 Billion KRW | 91.48% |
| 2012 | 10.77 Billion KRW | 9.11% |
| 2011 | 9.87 Billion KRW | 373.28% |
| 2010 | 2.08 Billion KRW | -41.52% |
| 2009 | 3.56 Billion KRW | -42.29% |
| 2008 | 6.18 Billion KRW | -11.57% |
| 2007 | 6.99 Billion KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 207.88 Billion KRW | 3.46% |
| 2024 Q2 | 215.29 Billion KRW | 3.56% |
| 2023 Q1 | 190.85 Billion KRW | -1.7% |
| 2023 FY | 200.94 Billion KRW | 3.5% |
| 2023 Q3 | 194.86 Billion KRW | -0.83% |
| 2023 Q4 | 200.94 Billion KRW | 3.12% |
| 2023 Q2 | 196.49 Billion KRW | 2.95% |
| 2022 Q4 | 194.15 Billion KRW | -0.09% |
| 2022 Q3 | 194.32 Billion KRW | 4.48% |
| 2022 FY | 194.15 Billion KRW | 38.12% |
| 2022 Q1 | 168.78 Billion KRW | 20.07% |
| 2022 Q2 | 185.98 Billion KRW | 10.19% |
| 2021 Q3 | 126.77 Billion KRW | 12.01% |
| 2021 Q2 | 113.18 Billion KRW | 45.1% |
| 2021 FY | 140.57 Billion KRW | 197.58% |
| 2021 Q1 | 78 Billion KRW | 65.13% |
| 2021 Q4 | 140.57 Billion KRW | 10.89% |
| 2020 FY | 47.23 Billion KRW | 69.74% |
| 2020 Q1 | 34.87 Billion KRW | 25.33% |
| 2020 Q2 | 42.47 Billion KRW | 21.79% |
| 2020 Q3 | 48.68 Billion KRW | 14.61% |
| 2020 Q4 | 47.23 Billion KRW | -2.97% |
| 2019 Q2 | 33.96 Billion KRW | 12.01% |
| 2019 Q3 | 12.65 Billion KRW | -62.73% |
| 2019 FY | 27.83 Billion KRW | 5.06% |
| 2019 Q4 | 27.83 Billion KRW | 119.86% |
| 2019 Q1 | 30.32 Billion KRW | 14.47% |
| 2018 Q2 | 32.03 Billion KRW | 1.73% |
| 2018 Q1 | 31.49 Billion KRW | -6.02% |
| 2018 Q4 | 26.48 Billion KRW | -21.56% |
| 2018 FY | 26.48 Billion KRW | -20.95% |
| 2018 Q3 | 33.77 Billion KRW | 5.4% |
| 2017 Q3 | 35.3 Billion KRW | 0.0% |
| 2017 FY | 33.51 Billion KRW | 7361.46% |
| 2017 Q4 | 33.51 Billion KRW | -5.08% |
| 2017 Q1 | 36.82 Billion KRW | 8099.79% |
| 2016 Q4 | 449.1 Million KRW | 0.0% |
| 2016 Q2 | 1.11 Billion KRW | -15.28% |
| 2016 FY | 449.1 Million KRW | 167.79% |
| 2016 Q1 | 1.31 Billion KRW | 298.16% |
| 2015 Q4 | -662.49 Million KRW | -120.21% |
| 2015 FY | -662.49 Million KRW | -105.15% |
| 2015 Q3 | 3.27 Billion KRW | -53.38% |
| 2015 Q2 | 7.03 Billion KRW | -34.92% |
| 2015 Q1 | 10.8 Billion KRW | -15.97% |
| 2014 Q4 | 12.85 Billion KRW | -30.84% |
| 2014 Q3 | 18.59 Billion KRW | 3.48% |
| 2014 Q1 | 15.51 Billion KRW | -24.77% |
| 2014 Q2 | 17.96 Billion KRW | 15.78% |
| 2014 FY | 12.85 Billion KRW | -37.67% |
| 2013 Q1 | 11.19 Billion KRW | 3.94% |
| 2013 Q3 | 19.47 Billion KRW | -2.27% |
| 2013 Q4 | 20.62 Billion KRW | 5.91% |
| 2013 Q2 | 19.93 Billion KRW | 77.98% |
| 2013 FY | 20.62 Billion KRW | 91.48% |
| 2012 Q1 | 4.09 Billion KRW | -58.52% |
| 2012 Q3 | 4.28 Billion KRW | -11.36% |
| 2012 Q4 | 10.77 Billion KRW | 151.59% |
| 2012 FY | 10.77 Billion KRW | 9.11% |
| 2012 Q2 | 4.83 Billion KRW | 17.94% |
| 2011 Q2 | 13.07 Billion KRW | 7.23% |
| 2011 Q1 | 12.19 Billion KRW | 484.37% |
| 2011 Q3 | 10.66 Billion KRW | -18.43% |
| 2011 Q4 | 9.87 Billion KRW | -7.41% |
| 2011 FY | 9.87 Billion KRW | 373.28% |
| 2010 Q3 | 1 Billion KRW | -67.35% |
| 2010 FY | 2.08 Billion KRW | -41.52% |
| 2010 Q4 | 2.08 Billion KRW | 107.42% |
| 2010 Q2 | 3.08 Billion KRW | 0.0% |
| 2009 FY | 3.56 Billion KRW | -42.29% |
| 2008 FY | 6.18 Billion KRW | -11.57% |
| 2007 FY | 6.99 Billion KRW | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -2182.897% |
| Dong-A Socio Holdings Co., Ltd. | 572.02 Billion KRW | 64.871% |
| Ildong Holdings Co., Ltd. | 310.87 Billion KRW | 35.36% |
| HANDOK Inc. | 283.45 Billion KRW | 29.108% |
| Kukje Pharma Co., Ltd. | 20.07 Billion KRW | -901.119% |
| Yuhan Corporation | -69.18 Billion KRW | 390.442% |
| Dong-A ST Co., Ltd. | 193.95 Billion KRW | -3.607% |
| SAMSUNG PHARM. Co., LTD. | -3.68 Billion KRW | 5551.884% |
| Hanmi Pharm. Co., Ltd. | 517.88 Billion KRW | 61.199% |
| Hanall Biopharma Co.,Ltd | -32.43 Billion KRW | 719.594% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | -165.54% |
| Dong Sung Bio Pharm.Co.,Ltd. | 36.83 Billion KRW | -445.496% |
| MYUNGMOON Pharm co.,Ltd | 82.52 Billion KRW | -143.512% |
| Hana Pharm Co., Ltd. | 25.1 Billion KRW | -700.315% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -2182.897% |
| Ilsung Pharmaceuticals Co., Ltd. | -159.84 Billion KRW | 225.711% |
| Aprogen pharmaceuticals,Inc. | 170.94 Billion KRW | -17.551% |
| JW Holdings Corporation | 480.68 Billion KRW | 58.196% |
| Ildong Pharmaceutical Co., Ltd. | 164.58 Billion KRW | -22.094% |
| Chong Kun Dang Pharmaceutical Corp. | 117.53 Million KRW | -170872.396% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | -30.171% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | -8446.112% |
| Hyundai Pharmaceutical Co., Ltd. | 23 Billion KRW | -773.625% |
| Samil Pharmaceutical Co.,Ltd | 174.97 Billion KRW | -14.844% |
| Jeil Pharmaceutical Co.,Ltd | 51.97 Billion KRW | -286.624% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -2182.897% |
| Kwang Dong Pharmaceutical Co., Ltd. | 158.29 Billion KRW | -26.943% |
| Daewoong pharmaceutical Co.,Ltd | 358.17 Billion KRW | 43.898% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | -30.171% |
| Yuhan Corporation | -69.18 Billion KRW | 390.442% |
| Jeil Pharma Holdings Inc | 135.99 Billion KRW | -47.764% |
| Yungjin Pharm. Co., Ltd. | 59.67 Billion KRW | -236.739% |
| Suheung Co., Ltd. | 429.14 Billion KRW | 53.175% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | -30.171% |
| Samjin Pharmaceuticals Co., Ltd. | 116.23 Billion KRW | -72.877% |
| Korea United Pharm Inc. | 16.42 Billion KRW | -1123.41% |
| CKD Bio Corp. | 143.29 Billion KRW | -40.231% |
| Daewon Pharmaceutical Co., Ltd. | 116.06 Billion KRW | -73.13% |
| Dongwha Pharm.Co.,Ltd | -24.06 Billion KRW | 935.129% |
| Whan In Pharm Co.,Ltd. | -44.73 Billion KRW | 549.202% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | -8446.112% |
| Chong Kun Dang Holdings Corp. | 422.84 Billion KRW | 52.477% |
| Boryung Corporation | 187.72 Billion KRW | -7.041% |
| Bukwang Pharmaceutical Co., Ltd. | -71.84 Billion KRW | 379.713% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | -165.54% |
| JW Lifescience Corporation | 26.09 Billion KRW | -670.184% |